Association Between Residual Platelet Reactivity on Clopidogrel Treatment and Severity of Coronary Atherosclerosis: Intrinsic Hypercoagulability as a Mediator

[1]  Marco Valgimigli,et al.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). , 2018, European heart journal.

[2]  P. Kolh,et al.  2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[3]  P. Kolh,et al.  [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.] , 2018, Kardiologia polska.

[4]  Nicholas J. Rockwood,et al.  Regression-based statistical mediation and moderation analysis in clinical research: Observations, recommendations, and implementation. , 2017, Behaviour research and therapy.

[5]  Peter L Duffy,et al.  Quantifying Ischemic Risk After Percutaneous Coronary Intervention Attributable to High Platelet Reactivity on Clopidogrel (From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents Study). , 2017, The American journal of cardiology.

[6]  Peter L Duffy,et al.  Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study. , 2017, JACC. Cardiovascular interventions.

[7]  Deepak L. Bhatt,et al.  Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease , 2017, The New England journal of medicine.

[8]  P. Serruys,et al.  Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study , 2017, European heart journal.

[9]  J. Ge,et al.  Thrombin induced platelet-fibrin clot strength in relation to platelet volume indices and inflammatory markers in patients with coronary artery disease , 2017, Oncotarget.

[10]  E. Ohman,et al.  Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial , 2017, The Lancet.

[11]  P. Gurbel,et al.  GEMINI-ACS-1: toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes , 2017, The Lancet.

[12]  Cheng-gang Zhu,et al.  Fibrinogen and the Severity of Coronary Atherosclerosis among Adults with and without Statin Treatment: Lipid as a mediator. , 2016, Heart, lung & circulation.

[13]  Jeroen J. Bax,et al.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.

[14]  B. Meyers,et al.  The American Association for Thoracic Surgery , 2016 .

[15]  Baris Gencer,et al.  ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation , 2011 .

[16]  R. Vettor,et al.  Hypercoagulability detected by whole blood thromboelastometry (ROTEM®) and impedance aggregometry (MULTIPLATE®) in obese patients. , 2015, Thrombosis research.

[17]  P. Kolh,et al.  2014 ESC/EACTS guidelines on myocardial revascularization. , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[18]  Cheng-gang Zhu,et al.  Higher Fibrinogen Level is Independently Linked with the Presence and Severity of New-Onset Coronary Atherosclerosis among Han Chinese Population , 2014, PloS one.

[19]  J. Ge,et al.  Thrombin induced platelet-fibrin clot strength measured by thrombelastography is a novel marker of platelet activation in acute myocardial infarction. , 2014, International journal of cardiology.

[20]  A. Shuldiner,et al.  Thrombin-induced platelet-fibrin clot strength: Relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes , 2013, Thrombosis and Haemostasis.

[21]  C. Esmon.  Targeting factor Xa and thrombin: impact on coagulation and beyond , 2013, Thrombosis and Haemostasis.

[22]  Deepak L. Bhatt,et al.  Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. , 2013, Journal of the American College of Cardiology.

[23]  Peter L Duffy,et al.  Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study , 2013, The Lancet.

[24]  R. Koppensteiner,et al.  Preserved thrombin‐inducible platelet activation in thienopyridine‐treated patients , 2013, European journal of clinical investigation.

[25]  P. Gurbel,et al.  Cigarette Smoking and Clopidogrel Interaction , 2013, Current Cardiology Reports.

[26]  A. Kastrati,et al.  Relation of fibrinogen level with cardiovascular events in patients with coronary artery disease. , 2013, The American journal of cardiology.

[27]  Antonio Colombo,et al.  Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II , 2013, The Lancet.

[28]  Antonio Colombo,et al.  Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial , 2013, The Lancet.

[29]  E. Mahmud,et al.  Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention. , 2013, Journal of the American College of Cardiology.

[30]  Sankey V. Williams,et al.  2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Ass , 2012, Journal of the American College of Cardiology.

[31]  E. Vicaut,et al.  Bedside monitoring to adjust antiplatelet therapy for coronary stenting. , 2012, The New England journal of medicine.

[32]  J. Gallacher,et al.  C-reactive protein, fibrinogen, and cardiovascular disease prediction. , 2012, The New England journal of medicine.

[33]  D. Atar,et al.  ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation , 2013 .

[34]  G. Stone,et al.  A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placem , 2012, Journal of the American College of Cardiology.

[35]  G. Dangas,et al.  High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study. , 2012, JACC. Cardiovascular imaging.

[36]  Paul Burton,et al.  Rivaroxaban in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.

[37]  Helmut Baumgartner,et al.  ESC / EACTS Guidelines on myocardial revascularization , 2014 .

[38]  G. Lippi,et al.  Arterial thrombus formation in cardiovascular disease , 2011, Nature Reviews Cardiology.

[39]  N. Schork,et al.  Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. , 2011, JAMA.

[40]  Deepak L. Bhatt,et al.  Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. , 2010, Journal of the American College of Cardiology.

[41]  P. Gurbel,et al.  Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. , 2010, American heart journal.

[42]  P. Gurbel,et al.  Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: Results of the Thrombotic RIsk Progression (TRIP) Study , 2010, Platelets.

[43]  C. Dethlefsen,et al.  Genetic susceptibility, smoking, obesity and risk of venous thromboembolism , 2010, British journal of haematology.

[44]  O. Muller,et al.  High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention. , 2010, JACC. Cardiovascular interventions.

[45]  M. Gawaz,et al.  Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. , 2010, European heart journal.

[46]  Antonio Colombo,et al.  Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. , 2009, The New England journal of medicine.

[47]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[48]  Jeffrey M Albert,et al.  Mediation analysis via potential outcomes models , 2008, Statistics in medicine.

[49]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[50]  H. Teede,et al.  Relationship of waist and hip circumference with coagulation and fibrinolysis in postmenopausal women. , 2007, Clinical science.

[51]  E. Mahmud,et al.  Elevated plasma fibrinogen level predicts suboptimal response to therapy with both single- and double-bolus eptifibatide during percutaneous coronary intervention. , 2007, Journal of the American College of Cardiology.

[52]  Mike W.-L. Cheung,et al.  Comparison of Approaches to Constructing Confidence Intervals for Mediating Effects Using Structural Equation Models , 2007 .

[53]  P. Gurbel,et al.  Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. , 2005, Journal of the American College of Cardiology.

[54]  K. Mann,et al.  Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography , 2005, Journal of thrombosis and haemostasis : JTH.

[55]  M. Woodward,et al.  A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C‐reactive protein following myocardial infarction: the CADET trial , 2004, Journal of thrombosis and haemostasis : JTH.

[56]  S. Yusuf,et al.  Oral anticoagulants in patients with coronary artery disease. , 2003, Journal of the American College of Cardiology.